In contrast, the OS curve for the 24 patients in the second subgroup–FLT3-ITD positive AML with co-occurring high-risk genetic changes (trisomy 8, TET2 and/or DNMT3A)–was similar to the OS curve for patients with unfavorable cytogenetics (adjusted p = 0.793) and significantly different from the OS curve for the intermediate IGP risk group (adjusted p = 0.022; Fig 2D). This evidence concerns the gene FLT3 and acute myeloid leukemia.